Determination of blood sample sensitivity
We extracted human blood samples 1 and 2 using a commercial blood magnetic bead extraction kit produced by BioDetect (Xiamen) Biotechnology Co., Ltd. and diluted them with a 10-fold gradient of 1X TE to obtain 1 ng/µl and 0.1 ng/µl samples. Each sample was independently tested five times, and the minimum detection limit of the blood sample genome was 0.1 ng/µl, as shown in Figure 7A-F. Among them, CYP2C19 * 2 in blood 1 sample was homozygous wild-type, CYP2C19 * 3 was heterozygous, and CYP2C19 * 17 was homozygous wild-type; in blood 2 sample, CYP2C19 * 2 was heterozygous, CYP2C19 * 3 was homozygous, and CYP2C19 * 17 was homozygous. We also detected 5 oropharyngeal samples and 5 saliva samples. For the oropharyngeal swabs, both sides of the mouth were gently sampled. The swabs with exfoliated oral cells were placed in the sample release agent, and the samples were shaken and mixed. For saliva, a collection tube was used; the sample was mixed with the release agent in equal proportion and shaken evenly for detection. The results for the oropharyngeal samples are shown in Figure S1A. Three cases of CYP2C19 * 2 heterozygosity, one case of CYP2C19 * 2 homozygous wild-type, one case of CYP2C19 * 2 homozygous mutation, five cases of CYP2C19 * 3 homozygous wild-type and five cases of CYP2C19 * 17 homozygous wild-type were successfully detected. The results for the saliva samples are shown in Figure S1B. Three cases of CYP2C19 * 2 heterozygosity, 2 cases of CYP2C19 * 2 homozygous wild-type, 1 case of CYP2C19 * 3 heterozygosity, 4 cases of CYP2C19 * 3 homozygous wild-type and 5 cases of CYP2C19 * 17 homozygous wild-type were successfully detected. Specific single peaks at each site were accurately observed.